US Patent

US7807708 — Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof

Composition of Matter · Assigned to Galderma Research and Development SNC · Expires 2031-07-19 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel ligand compounds and pharmaceutical or cosmetic compositions containing them, useful in human and veterinary medicine or cosmetics.

USPTO Abstract

Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.

Drugs covered by this patent

Patent Metadata

Patent number
US7807708
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-07-19
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Galderma Research and Development SNC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.